Gelder Mark S. MD 4
4 · Onconova Therapeutics, Inc. · Filed Mar 14, 2023
Insider Transaction Report
Form 4
Gelder Mark S. MD
Chief Medical Officer
Transactions
- Award
Restricted Stock Units
2023-03-13+20,667→ 20,667 total→ Common Stock (20,667 underlying) - Award
Stock Option (right to purchase)
2023-03-13+62,000→ 62,000 totalExercise: $0.73Exp: 2033-03-13→ Common Stock (62,000 underlying)
Footnotes (3)
- [F1]These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
- [F2]Each restricted stock unit is convertible into one share of common stock.
- [F3]These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary